SCHEMBL6473079

SCHEMBL6473079

CC(C)(CCN1C(=O)c2ccccc2C1=O)COC1CCCCO1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ACHE P22303 2/20 0.42
LMNA P02545 1/20 0.40
HTR1A P08908 1/20 0.38
HTR7 P34969 1/20 0.38
HRH1 P35367 1/20 0.38
DRD3 P35462 1/20 0.38
HTR2B P41595 1/20 0.38
CHRM2 P08172 1/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
MAPK1 P28482 2/20 0.37
KDM4E B2RXH2 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
TP53 P04637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6387778 0.93 LMNA (0.43) CYP1A2CYP2C9CYP2C19ACHELMNA
SCHEMBL6390234 0.92 HTR1A (0.43) CYP1A2CYP2C9CYP2C19ACHELMNA
SCHEMBL6388864 0.82 TDP1 (0.37) CYP1A2CYP2C9CYP2C19LMNAALDH1A1
SCHEMBL6532909 0.80 LMNA (0.40) CYP1A2CYP2C9CYP2C19ACHELMNA
SCHEMBL9053482 0.79 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19ACHELMNA
SCHEMBL29929381 0.79 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19ACHELMNA
SCHEMBL20548002 0.79 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19ACHELMNA
SCHEMBL20547967 0.79 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19ACHELMNA
SCHEMBL28910814 0.79 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19ACHELMNA
SCHEMBL21069711 0.77 HPGD (0.46) CYP1A2CYP2C9CYP2C19LMNAHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1495034-A2 MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES Esperion Therapeutics, Inc. (US) 2005-01-12 EP disclosed
US-20030236213-A1 Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses ESPERION THERAPEUTICS 2003-12-25 US disclosed
WO-2003087040-A2 MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236213-A1 Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses COASY, HMGCR, ACACA CYP1A2 809/4885CYP2C9 440/4885CYP2C19 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.